SCHEMBL20161328

SCHEMBL20161328

CCOC(=O)C(=O)NC(Cc1ccccc1F)c1cnccn1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 1/20 0.37
GAA P10253 5/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.35
NPC1 O15118 3/20 0.35
GLA P06280 1/20 0.35
TSHR P16473 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SGMS2 Q8NHU3 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21775376 0.82 CTDSP1 (0.44) SMN1; SMN2LMNAGAAKDM4EALDH1A1
SCHEMBL20139640 0.75 GAA (0.46) SMN1; SMN2LMNAGAAKDM4EALDH1A1
SCHEMBL1128211 0.69 KMT2A (0.52) SMN1; SMN2LMNAGAAKDM4EALDH1A1
SCHEMBL20161327 0.68 NPC1 (0.38) PKMNPC1RAB9A
SCHEMBL5229869 0.67 GAA (0.50) SMN1; SMN2GAAKDM4EALDH1A1PKM
SCHEMBL1127307 0.67 KMT2A (0.49) SMN1; SMN2LMNAGAAKDM4EALDH1A1
SCHEMBL11543325 0.66 KDM4E (0.54) SMN1; SMN2GAAKDM4EALDH1A1PKM
SCHEMBL8638253 0.66 ALDH1A1 (0.50) SMN1; SMN2LMNAKDM4EALDH1A1TDP1
SCHEMBL8219962 0.65 SMN1; SMN2 (0.47) SMN1; SMN2LMNAGAAKDM4EALDH1A1
SCHEMBL6379502 0.65 TACR1 (0.50) LMNAKDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A SMN1; SMN2 1010/4885LMNA 3196/4885GAA 190/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A SMN1; SMN2 1049/4885LMNA 3153/4885GAA 189/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A SMN1; SMN2 1049/4885LMNA 3153/4885GAA 189/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A SMN1; SMN2 1010/4885LMNA 3196/4885GAA 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.